2026 Mechanic hands syndrome indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Amyopathic dermatomyositis indication strategy covering epidemiology, IFNAR biology, active trials, transactions, unmet need, competition and market…

2026 Dermatomyositis skin disease indication strategy covering epidemiology, IFNAR biology, active trials, transactions, unmet need, competition and market…

2026 Neonatal lupus erythematosus indication strategy covering epidemiology, IFNAR biology, active trials, transactions, unmet need, competition and market…

2026 Rowell syndrome indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Tumid lupus erythematosus indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…

2026 Subacute cutaneous lupus erythematosus indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and…

2026 Folliculitis decalvans indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Erosive pustular dermatosis of the scalp indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and…

2026 Perifolliculitis capitis abscedens et suffodiens indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need,…

2026 Acne fulminans indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Hidradenitis suppurativa Hurley stage III indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and…